Anzeige
Mehr »
Samstag, 09.08.2025 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CQ56 | ISIN: US23954D1090 | Ticker-Symbol:
NASDAQ
08.08.25 | 22:00
6,100 US-Dollar
+1,16 % +0,070
1-Jahres-Chart
DAY ONE BIOPHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
DAY ONE BIOPHARMACEUTICALS INC 5-Tage-Chart

Aktuelle News zur DAY ONE BIOPHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiDay One Biopharmaceuticals outlines $140M-$150M 2025 OJEMDA revenue target as new patient scripts accelerate6
DiDay One Biopharmaceuticals: Umsatzwachstum bei OJEMDA hält an, während die Entwicklungspipeline voranschreitet15
DiDay One Biopharmaceuticals Non-GAAP EPS of -$0.29 beats by $0.05, revenue of $33.91M misses by $0.99M16
DiDay One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report3
DiDay One Biopharmaceuticals, Inc. - 8-K, Current Report1
22.07.Day One Biopharmaceuticals, Inc.: Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 20253
23.06.TimesSquare Capital U.S. Small Cap Growth Strategy Exited its Position in Day One Biopharmaceuticals Inc. (DAWN)7
10.06.Day One Biopharmaceuticals, Inc.: Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development5
DAY ONE BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln
03.06.Day One Biopharmaceuticals, Inc. - 8-K, Current Report3
06.05.Day One Biopharmaceuticals, Inc.: Day One Reports First Quarter 2025 Financial Results and Corporate Progress448OJEMDA (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in...
► Artikel lesen
06.05.Day One Biopharmaceuticals, Inc. - 10-Q, Quarterly Report1
06.05.Day One Biopharmaceuticals, Inc. - 8-K, Current Report1
22.04.Day One Biopharmaceuticals, Inc.: Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 20258
03.04.H.C. Wainwright maintains Buy on Day One Biopharmaceuticals12
06.03.Day One Biopharmaceuticals, Inc. - 10-K/A, Annual Report1
26.02.Day One Biopharmaceuticals stock target cut to $36 at H.C. Wainwright8
25.02.Day One Biopharmaceuticals GAAP EPS of -$1.02 misses by $0.29, revenue of $131.16M beats by $8.64M2
25.02.Day One Biopharmaceuticals, Inc. - 8-K, Current Report1
11.02.Day One Biopharmaceuticals, Inc.: Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 20257
30.10.24Day One Biopharmaceuticals, Inc.: Day One Reports Third Quarter 2024 Financial Results and Corporate Progress511Achieved $20.1 million in OJEMDATM (tovorafenib) net product revenue Ended the third quarter with $558.4 million in cash, cash equivalents and short-term investments Company to host conference call...
► Artikel lesen
20 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,28,56